Effect of Statin on the 5 Years Clinical Outcomes in Dialysis Patients Treated with Sirolimus-eluting Stent
スポンサーリンク
概要
- 論文の詳細を見る
Objective The optimal medication therapies are recommended in patients with coronary artery disease even after the coronary revascularization. However, the information of optimal medical therapy in dialysis population is scant. We assessed the efficacy of statin on the clinical outcomes after Sirolimus-eluting stent (SES) implantation in patients with and without dialysis. Methods and Results We analyzed date from 843 consecutive patients who successfully treated with SES in our institution between August 2004 and November 2006. Among patients, 96 patients (11.4%) were undergoing dialysis. In non-dialysis patients, 405 patients (54%) were treated with statin at hospital discharge. In dialysis patients, only 16 patients (17%) were treated with statin. In non-dialysis patients, mortality rate was significantly lower in patients treated with statin than those without statin (4.4% vs. 13.9%, p<0.0001). While in dialysis patients, mortality rate was similar between patients treated with and without statin (56.3% vs. 57.6%, p=0.86). After adjusting for confounders, the hazard ratios for mortality were 0.39 (95% confidence interval (CI), 0.14-0.99; p=0.047) in non-dialysis patients and 1.79 (95% CI, 0.39-7.86; 0.45) for dialysis patients. The interaction probability between statin use and dialysis for mortality was 0.016. Conclusion The use of statin may have beneficial effect on reducing mortality rate in patients after SES implantation in non-dialysis patients. However, such favorable effect was not observed in dialysis population.
- 一般社団法人 日本内科学会の論文
一般社団法人 日本内科学会 | 論文
- A Patient with Diffuse Cutaneous Systemic Sclerosis Complicated by Antineutrophil-cytoplasmic Antibody-associated Vasculitis Exhibiting Honeycomb Lung without Volume Loss
- Parkinson's Disease and the Cardio-ankle Vascular Stiffness Index
- Pseudohypoparathyroidism Type II in a Woman with a History of Thyroid Surgery
- A Novel Frameshift Mutation in Exon 4 Causing a Deficiency of High-molecular-weight Kininogen in a Patient with Splenic Infarction
- Risk Factors for Liver Injury with an Elevated Serum Bilirubin Concentration Caused by Antituberculous Drugs